ClinicalTrials.Veeva

Menu

Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa

H

HIV Prevention Trials Network

Status

Completed

Conditions

HIV

Treatments

Other: Observational

Study type

Observational

Funder types

NETWORK
NIH

Identifiers

NCT03201510
UM1AI068619 (U.S. NIH Grant/Contract)
HPTN 075

Details and patient eligibility

About

This study aims to determine the feasibility of recruiting and retaining men who have sex with men (MSM) in a multi-country prospective cohort study in preparation for human immunodeficiency virus (HIV) prevention studies in sub-Saharan Africa (SSA).

Full description

HPTN 075 is an observational cohort study. Participants will be accrued over six months at four sites in SSA using convenience sampling strategies, with no replacement for participants lost to follow-up. Each participant will be followed for 12 months, during which five study visits involving structured HIV behavioral assessments, medical examinations, and collection of biological samples will be conducted (including enrollment and quarterly follow-up visits). Participants who do not complete 12 months of follow-up will be contacted to explore reasons for no longer participating.

Enrollment

401 patients

Sex

Male

Ages

18 to 44 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Biologically male at birth, according to self-report;
  • 18-44 years old (inclusive);
  • Willing and able to provide informed consent;
  • Willing to undergo HIV testing throughout the study and to receive those test results;
  • Reporting at least one act of anal intercourse in the previous 3 months (12 weeks) with a person reported by the participant to be biologically male;
  • Able to provide complete locator identification for themselves and at least two other personal contacts;
  • Willing to participate in all scheduled study assessments, including specimen collection, laboratory assessments, and sample storage;
  • Committing to not participate in any HIV intervention or vaccine study while participating in HPTN 075;
  • Planning to remain in the study area for at least one year;
  • For HIV-uninfected men: All HIV test results at the Screening visit must be non-reactive/negative;
  • For HIV-infected men (up to 20 per site): All HIV test results at the Screening visit must be reactive/positive.

Men who are already on PrEP will not be excluded. Additionally, self- or other-identified transgender women and male sex workers will not be excluded. There will, however, be no specific effort to recruit these groups.

Exclusion criteria

  • Unwilling to adhere to study procedures;
  • Past or current participation in a biomedical and/or behavioral HIV/STI intervention or cohort study, including HIV vaccine studies; however, participation in local/area PrEP demonstration projects does not preclude participation in HPTN 075;
  • HIV-infected men who report that they are already on ART or in HIV care;
  • Any other reason or condition that in the opinion of the Investigator of Record (IOR) would interfere with participation, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
  • Men who have discordant HIV test results at Screening (i.e., at least one reactive or positive result and at least one non-reactive or negative result). These men will receive HIV counseling and will be referred for further diagnostic tests and care.

Trial design

401 participants in 1 patient group

Observational
Description:
Observational study
Treatment:
Other: Observational

Trial documents
1

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems